Mithramycin and analogs for overcoming cisplatin resistance in ovarian cancer

David Schweer, J. Robert McCorkle, Jurgen Rohr, Oleg V. Tsodikov, Frederick Ueland, Jill Kolesar

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

Ovarian cancer is a highly deadly malignancy in which recurrence is considered incurable. Resistance to platinum-based chemotherapy bodes a particularly abysmal prognosis, underscoring the need for novel therapeutic agents and strategies. The use of mithramycin, an antineoplastic antibiotic, has been previously limited by its narrow therapeutic window. Recent advances in semisynthetic methods have led to mithramycin analogs with improved pharmacological profiles. Mithramycin inhibits the activity of the transcription factor Sp1, which is closely linked with ovarian tumorigenesis and platinum-resistance. This article summarizes recent clinical developments related to mithramycin and postulates a role for the use of mithramycin, or its analog, in the treatment of platinum-resistant ovarian cancer.

Original languageEnglish
Article number70
Pages (from-to)1-11
Number of pages11
JournalBiomedicines
Volume9
Issue number1
DOIs
StatePublished - Jan 1 2021

Bibliographical note

Funding Information:
Funding: This research was funded by a NIH Training Grant, T32CA160003, the 2020 Inter-Departmental Collaboration (IDC) Award from the University of Kentucky College of Pharmacy, and by the University of Kentucky Markey Cancer Center (P30 CA177558)

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.

Keywords

  • Mithramycin
  • Novel therapeutics
  • Ovarian cancer
  • Platinum-resistant
  • Sp1

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology (all)

Fingerprint

Dive into the research topics of 'Mithramycin and analogs for overcoming cisplatin resistance in ovarian cancer'. Together they form a unique fingerprint.

Cite this